<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829177</url>
  </required_header>
  <id_info>
    <org_study_id>3004</org_study_id>
    <nct_id>NCT02829177</nct_id>
  </id_info>
  <brief_title>Microalbuminuria and Allopurinol in Type 1 Diabetes</brief_title>
  <acronym>MIKAL</acronym>
  <official_title>A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Rossing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine if lowering serum uric acid by means of allopurinol in the
      course of kidney disease may be effective in preventing or improving albuminuria and renal
      function in Type 1 Diabetic patients. The study is a double blinded, randomised,
      placebo-controlled cross-over clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved Albuminuria</measure>
    <time_frame>60 days</time_frame>
    <description>Improvement of albuminuria will be evaluated by the collection of 24h urin collection with the measure of 24h albumine excretion rate and the measurements will be compared for the two treatment arm for each participant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg once daily, tablet treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical tablet treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Albuminuria (≥30 mg/g)

          -  Uric Acid ≥ 0,265 mmol/l

          -  GFR (glomerular filtration rate) &gt; 40 ml/min/1.73m2

        Exclusion Criteria:

          -  History of gout or xanthinuria or other indications for uric acid lowering therapy
             such as cancer chemotherapy.

          -  Recurrent renal calculi.

          -  Current use of azathioprine, 6-mercaptopurine, didanosine, tamoxifen,
             amoxicillin/ampicillin, or other drugs interacting with allopurinol.

          -  Known allergy to xanthine-oxidase inhibitors.

          -  Renal transplant.

          -  Non-diabetic kidney disease.

          -  Home, 24h og clinical BP&gt;180 or Diastolic BP &gt;130 mmHg at screening.

          -  Cancer treatment within two years before screening.

          -  History of hepatitis B or C.

          -  History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)
             infection.

          -  History of alcohol or drug abuse.

          -  Breastfeeding or pregnancy or unwillingness to be on contraception throughout the
             trial.

          -  Poor mental function or any other reason to expect patient difficulty in complying
             with the requirements of the study.

          -  Serious pre-existing medical problems other than diabetes, e.g. congestive heart
             failure, pulmonary insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center</investigator_affiliation>
    <investigator_full_name>Peter Rossing</investigator_full_name>
    <investigator_title>Senior Principal Investigator, Professor, Chief Physician, DMSc</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>Allopurinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

